Sp781

ROLE OF CREEPING FAT IN RECURRENT STRICTURES: A SURGEON’S PERSPECTIVE

Date
May 20, 2024

Presenter

Speaker Image for Phillip Fleshner
Cedars-Sinai Medical Center

Tracks

Related Products

Thumbnail for CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
BACKGROUND: Our previous research has showed that increased sympathetic nervous activity and decreased cannabinoid receptor 1 (CB1) were associated with increased energy expenditure and weight loss following Roux-en-Y gastric bypass (RYGB) in mice…
Thumbnail for COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
BACKGROUND: Siewert's topographic classification (SW) has been used for treatment plan of esophagogastric junction adenocarcinomas (EGJA). But recently, molecular classifications categorized EGJA with similar characteristics and prognosis…
Thumbnail for MULTIMODAL PREHABILITATION IS ASSOCIATED WITH IMPROVED SURGICAL OUTCOMES IN IBD
MULTIMODAL PREHABILITATION IS ASSOCIATED WITH IMPROVED SURGICAL OUTCOMES IN IBD
BACKGROUND: Multimodal prehabilitation (MPH) including medical and nutrition counseling and physical therapy improves outcomes after cancer surgery. However, the effects of MPH for IBD surgery are not established…
Thumbnail for SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…